BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Knyazev OV, Parfenov AI, Konoplyannikov AG, Ruchkina IN, Churikova AA, Bykova SV, Albulova EA, Boldyreva ON, Fadeeva NA, Lishchinskaya AA. [Safety of mesenchymal stromal cell therapy for inflammatory bowel diseases: results of a 5-year follow-up]. Ter Arkh 2015;87:39-44. [PMID: 25864347 DOI: 10.17116/terarkh201587239-44] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Obi ON, Lower EE, Baughman RP. Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. Expert Rev Clin Pharmacol 2021;14:179-210. [PMID: 33487042 DOI: 10.1080/17512433.2021.1878024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ko JZ, Johnson S, Dave M. Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review.Biomolecules. 2021;11. [PMID: 33440772 DOI: 10.3390/biom11010082] [Cited by in Crossref: 7] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
3 Cao H, Liu J, Shen P, Cai J, Han Y, Zhu K, Fu Y, Zhang N, Zhang Z, Cao Y. Protective Effect of Naringin on DSS-Induced Ulcerative Colitis in Mice. J Agric Food Chem. 2018;66:13133-13140. [PMID: 30472831 DOI: 10.1021/acs.jafc.8b03942] [Cited by in Crossref: 39] [Cited by in F6Publishing: 63] [Article Influence: 9.8] [Reference Citation Analysis]
4 Dave M, Jaiswal P, Cominelli F. Mesenchymal stem/stromal cell therapy for inflammatory bowel disease: an updated review with maintenance of remission. Curr Opin Gastroenterol. 2017;33:59-68. [PMID: 28134690 DOI: 10.1097/mog.0000000000000327] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
5 Ibraheim H, Giacomini C, Kassam Z, Dazzi F, Powell N. Advances in mesenchymal stromal cell therapy in the management of Crohn's disease. Expert Rev Gastroenterol Hepatol 2018;12:141-53. [PMID: 29096549 DOI: 10.1080/17474124.2018.1393332] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
6 Qiu Y, Li MY, Feng T, Feng R, Mao R, Chen BL, He Y, Zeng ZR, Zhang SH, Chen MH. Systematic review with meta-analysis: the efficacy and safety of stem cell therapy for Crohn's disease. Stem Cell Res Ther 2017;8:136. [PMID: 28583202 DOI: 10.1186/s13287-017-0570-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
7 Wang D, Niu L, Feng X, Yuan X, Zhao S, Zhang H, Liang J, Zhao C, Wang H, Hua B, Sun L. Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study.Clin Exp Med. 2017;17:333-340. [PMID: 27270729 DOI: 10.1007/s10238-016-0427-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
8 Algeri M, Conforti A, Pitisci A, Starc N, Tomao L, Bernardo ME, Locatelli F. Mesenchymal stromal cells and chronic inflammatory bowel disease. Immunol Lett. 2015; Jul 10. [Epub ahead of print]. [PMID: 26170204 DOI: 10.1016/j.imlet.2015.06.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]